CHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo

Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has recommended approval of Opdivo (nivolumab) for another indication. The CHMP recommended approval of Opdivo in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by Opdivo as monotherapy as adjuvant treatment after surgical resection for the treatment of resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in adult patient ...